Search

Your search keyword '"Karpenko, Larisa I."' showing total 20 results
Start Over Author "Karpenko, Larisa I." Publication Year Range Last 3 years
20 results on '"Karpenko, Larisa I."'

1. DNA Vaccine Encoding a Modified Hemagglutinin Trimer of Avian Influenza A Virus H5N8 Protects Mice from Viral Challenge

Author

Litvinova, Victoria R., primary, Rudometov, Andrey P., additional, Rudometova, Nadezhda B., additional, Kisakov, Denis N., additional, Borgoyakova, Mariya B., additional, Kisakova, Lyubov A., additional, Starostina, Ekaterina V., additional, Fando, Anastasia A., additional, Yakovlev, Vladimir A., additional, Tigeeva, Elena V., additional, Ivanova, Ksenia I., additional, Gudymo, Andrei S., additional, Ilyicheva, Tatiana N., additional, Marchenko, Vasiliy Yu., additional, Sergeev, Artemiy A., additional, Ilyichev, Alexander A., additional, and Karpenko, Larisa I., additional

Published
2024
Full Text
View/download PDF

2. Immunogenicity and Protective Efficacy of a Single Intranasal Dose Vectored Vaccine Based on Sendai Virus (Moscow Strain) against SARS-CoV-2 Variant of Concern.

Author

Kochneva, Galina V., Kudrov, Gleb A., Zainutdinov, Sergei S., Shulgina, Irina S., Shipovalov, Andrei V., Zaykovskaya, Anna V., Borgoyakova, Mariya B., Starostina, Ekaterina V., Bodnev, Sergei A., Sivolobova, Galina F., Grazhdantseva, Antonina A., Ivkina, Daria I., Zadorozhny, Alexey M., Karpenko, Larisa I., and P'yankov, Oleg V.

Subjects
SARS-CoV-2 Delta variant, SENDAI virus, INTRANASAL administration, GOLDEN hamster, SARS-CoV-2
Abstract

The mouse paramyxovirus Sendai, which is capable of limited replication in human bronchial epithelial cells without causing disease, is well suited for the development of vector-based intranasal vaccines against respiratory infections, including SARS-CoV-2. Using the Moscow strain of the Sendai virus, we developed a vaccine construct, Sen-Sdelta(M), which expresses the full-length spike (S) protein of the SARS-CoV-2 delta variant. A single intranasal delivery of Sen-Sdelta(M) to Syrian hamsters and BALB/c mice induced high titers of virus-neutralizing antibodies specific to the SARS-CoV-2 delta variant. A significant T-cell response, as determined by IFN-γ ELISpot and ICS methods, was also demonstrated in the mouse model. Mice and hamsters vaccinated with Sen-Sdelta(M) were well protected against SARS-CoV-2 challenge. The viral load in the lungs and nasal turbinates, measured by RT-qPCR and TCID50 assay, decreased dramatically in vaccinated groups. The most prominent effect was revealed in a highly sensitive hamster model, where no tissue samples contained detectable levels of infectious SARS-CoV-2. These results indicate that Sen-Sdelta(M) is a promising candidate as a single-dose intranasal vaccine against SARS-CoV-2, including variants of concern. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Immunogenic and Protective Properties of Recombinant Hemagglutinin of Influenza A (H5N8) Virus.

Author

Rudometova, Nadezhda B., Fando, Anastasia A., Kisakova, Lyubov A., Kisakov, Denis N., Borgoyakova, Mariya B., Litvinova, Victoria R., Yakovlev, Vladimir A., Tigeeva, Elena V., Vahitov, Danil I., Sharabrin, Sergey V., Shcherbakov, Dmitriy N., Evseenko, Veronika I., Ivanova, Ksenia I., Gudymo, Andrei S., Ilyicheva, Tatiana N., Marchenko, Vasiliy Yu., Ilyichev, Alexander A., Rudometov, Andrey P., and Karpenko, Larisa I.

Subjects
CHO cell, HEMAGGLUTININ, INFLUENZA, INTRAMUSCULAR injections, IMMUNE response
Abstract

In this study, we characterized recombinant hemagglutinin (HA) of influenza A (H5N8) virus produced in Chinese hamster ovary cells (CHO-K1s). Immunochemical analysis showed that the recombinant hemagglutinin was recognized by the serum of ferrets infected with influenza A (H5N8) virus, indicating that its antigenic properties were retained. Two groups of Balb/c mice were immunized with intramuscular injection of recombinant hemagglutinin or propiolactone inactivated A/Astrakhan/3212/2020 (H5N8) influenza virus. The results demonstrated that both immunogens induced a specific antibody response as determined by ELISA. Virus neutralization assay revealed that sera of immunized animals were able to neutralize A/turkey/Stavropol/320-01/2020 (H5N8) influenza virus—the average neutralizing titer was 2560. Immunization with both recombinant HA/H5 hemagglutinin and inactivated virus gave 100% protection against lethal H5N8 virus challenge. This study shows that recombinant HA (H5N8) protein may be a useful antigen candidate for developing subunit vaccines against influenza A (H5N8) virus with suitable immunogenicity and protective efficacy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. The use of electroporation to deliver DNA-based vaccines.

Author

Kisakov, Denis N, Belyakov, Igor M., Kisakova, Lubov A, Yakovlev, Vladimir A, Tigeeva, Elena V, and Karpenko, Larisa I

Abstract

Introduction: Nucleic acids represent a promising platform for creating vaccines. One disadvantage of this approach is its relatively low immunogenicity. Electroporation (EP) is an effective way to increase the DNA vaccines immunogenicity. However, due to the different configurations of devices used for EP, EP protocols optimization is required not only to enhance immunogenicity, but also to ensure greater safety and tolerability of the EP procedure. Area covered: An data analysis for recent years on the DNA vaccines delivery against viral and parasitic infections using EP was carried out. The study of various EP physical characteristics, such as frequency, pulse duration, pulse interval, should be considered along with the immunogenic construct design and the site of delivery of the vaccine, through the study of the immunogenic and protective characteristics of the latter. Expert opinion: Future research should focus on regulating the humoral and cellular response required for protection against infectious agents by modifying the EP protocol. Significant efforts will be directed to establishing the possibility of redirecting the immune response toward the Th1 or Th2 response by changing the EP physical parameters. It will allow for an individual selective approach during EP, depending on the pathogen type of an infectious disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. SARS-CoV-2 RBD Conjugated to Polyglucin, Spermidine, and dsRNA Elicits a Strong Immune Response in Mice

Author

Volosnikova, Ekaterina A., primary, Merkuleva, Iuliia A., additional, Esina, Tatiana I., additional, Shcherbakov, Dmitry N., additional, Borgoyakova, Mariya B., additional, Isaeva, Anastasiya A., additional, Nesmeyanova, Valentina S., additional, Volkova, Natalia V., additional, Belenkaya, Svetlana V., additional, Zaykovskaya, Anna V., additional, Pyankov, Oleg V., additional, Starostina, Ekaterina V., additional, Zadorozhny, Alexey M., additional, Zaitsev, Boris N., additional, Karpenko, Larisa I., additional, Ilyichev, Alexander A., additional, and Danilenko, Elena D., additional

Published
2023
Full Text
View/download PDF

9. Comparison of the Effectiveness of Transepidemal and Intradermal Immunization of Mice with the Vacinia Virus

Author

Shchelkunov, Sergei N., primary, Sergeev, Aleksander A., additional, Titova, Ksenia A., additional, Pyankov, Stepan A., additional, Starostina, Ekaterina V., additional, Borgoyakova, Maria B., additional, Kisakova, Lubov A., additional, Kisakov, Denis N., additional, Karpenko, Larisa I., additional, and Yakubitskiy, Stanislav N., additional

Published
2023
Full Text
View/download PDF

15. Enhancing the Immunogenicity of Vaccinia Virus

Author

Shchelkunov, Sergei N., primary, Yakubitskiy, Stanislav N., additional, Sergeev, Alexander A., additional, Starostina, Ekaterina V., additional, Titova, Ksenia A., additional, Pyankov, Stepan A., additional, Shchelkunova, Galina A., additional, Borgoyakova, Mariya B., additional, Zadorozhny, Alexey M., additional, Orlova, Lyubov A., additional, Kisakov, Denis N., additional, and Karpenko, Larisa I., additional

Published
2022
Full Text
View/download PDF

16. Are Hamsters a Suitable Model for Evaluating the Immunogenicity of RBD-Based Anti-COVID-19 Subunit Vaccines?

Author

Merkuleva, Iuliia A., primary, Shcherbakov, Dmitry N., additional, Borgoyakova, Mariya B., additional, Isaeva, Anastasiya A., additional, Nesmeyanova, Valentina S., additional, Volkova, Natalia V., additional, Aripov, Vazirbek S., additional, Shanshin, Daniil V., additional, Karpenko, Larisa I., additional, Belenkaya, Svetlana V., additional, Kazachinskaia, Elena I., additional, Volosnikova, Ekaterina A., additional, Esina, Tatiana I., additional, Sergeev, Alexandr A., additional, Titova, Kseniia A., additional, Konyakhina, Yulia V., additional, Zaykovskaya, Anna V., additional, Pyankov, Oleg V., additional, Kolosova, Evgeniia A., additional, Viktorina, Olesya E., additional, Shelemba, Arseniya A., additional, Rudometov, Andrey P., additional, and Ilyichev, Alexander A., additional

Published
2022
Full Text
View/download PDF

17. Self-Assembled Particles Combining SARS-CoV-2 RBD Protein and RBD DNA Vaccine Induce Synergistic Enhancement of the Humoral Response in Mice

Author

Borgoyakova, Mariya B., primary, Karpenko, Larisa I., additional, Rudometov, Andrey P., additional, Volosnikova, Ekaterina A., additional, Merkuleva, Iuliia A., additional, Starostina, Ekaterina V., additional, Zadorozhny, Alexey M., additional, Isaeva, Anastasiya A., additional, Nesmeyanova, Valentina S., additional, Shanshin, Daniil V., additional, Baranov, Konstantin O., additional, Volkova, Natalya V., additional, Zaitsev, Boris N., additional, Orlova, Lyubov A., additional, Zaykovskaya, Anna V., additional, Pyankov, Oleg V., additional, Danilenko, Elena D., additional, Bazhan, Sergei I., additional, Shcherbakov, Dmitry N., additional, Taranin, Alexander V., additional, and Ilyichev, Alexander A., additional

Published
2022
Full Text
View/download PDF

18. Comparative Immunogenicity of the Recombinant Receptor-Binding Domain of Protein S SARS-CoV-2 Obtained in Prokaryotic and Mammalian Expression Systems

Author

Merkuleva, Iuliia A., primary, Shcherbakov, Dmitry N., additional, Borgoyakova, Mariya B., additional, Shanshin, Daniil V., additional, Rudometov, Andrey P., additional, Karpenko, Larisa I., additional, Belenkaya, Svetlana V., additional, Isaeva, Anastasiya A., additional, Nesmeyanova, Valentina S., additional, Kazachinskaia, Elena I., additional, Volosnikova, Ekaterina A., additional, Esina, Tatiana I., additional, Zaykovskaya, Anna V., additional, Pyankov, Oleg V., additional, Borisevich, Sophia S., additional, Shelemba, Arseniya A., additional, Chikaev, Anton N., additional, and Ilyichev, Alexander A., additional

Published
2022
Full Text
View/download PDF

19. Synthesis and In Vitro Study of Antiviral Activity of Glycyrrhizin Nicotinate Derivatives against HIV-1 Pseudoviruses and SARS-CoV-2 Viruses

Author

Fomenko, Vladislav V., primary, Rudometova, Nadezhda B., additional, Yarovaya, Olga I., additional, Rogachev, Artem D., additional, Fando, Anastasia A., additional, Zaykovskaya, Anna V., additional, Komarova, Nina I., additional, Shcherbakov, Dmitry N., additional, Pyankov, Oleg V., additional, Pokrovsky, Andrey G., additional, Karpenko, Larisa I., additional, Maksyutov, Rinat A., additional, and Salakhutdinov, Nariman F., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results